Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 7 | 2024 | 287 | 2.410 |
Why?
|
| Head and Neck Neoplasms | 3 | 2022 | 1060 | 1.110 |
Why?
|
| Metals | 2 | 2016 | 93 | 1.020 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2016 | 63 | 1.020 |
Why?
|
| Radiotherapy, Image-Guided | 3 | 2020 | 58 | 0.920 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 21 | 0.820 |
Why?
|
| Chemoradiotherapy | 3 | 2022 | 309 | 0.800 |
Why?
|
| Pneumonia | 1 | 2022 | 183 | 0.720 |
Why?
|
| Fiducial Markers | 1 | 2020 | 7 | 0.700 |
Why?
|
| Phantoms, Imaging | 2 | 2020 | 453 | 0.670 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2017 | 366 | 0.640 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2020 | 185 | 0.630 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 950 | 0.610 |
Why?
|
| Artifacts | 2 | 2016 | 246 | 0.590 |
Why?
|
| Movement | 1 | 2020 | 310 | 0.580 |
Why?
|
| Dental Restoration, Permanent | 1 | 2016 | 2 | 0.550 |
Why?
|
| Dental Implants | 1 | 2016 | 11 | 0.540 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 1125 | 0.540 |
Why?
|
| Software | 1 | 2020 | 666 | 0.510 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 2364 | 0.490 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 1221 | 0.450 |
Why?
|
| Neoplasms | 3 | 2024 | 3053 | 0.380 |
Why?
|
| Algorithms | 2 | 2016 | 1896 | 0.370 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 1097 | 0.350 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 1732 | 0.310 |
Why?
|
| Organ Sparing Treatments | 2 | 2017 | 46 | 0.280 |
Why?
|
| Radiation Oncology | 2 | 2020 | 121 | 0.280 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 2003 | 0.270 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 1064 | 0.260 |
Why?
|
| Humans | 16 | 2024 | 89567 | 0.230 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 606 | 0.220 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 65 | 0.220 |
Why?
|
| Combined Modality Therapy | 3 | 2024 | 1705 | 0.210 |
Why?
|
| Cetuximab | 1 | 2022 | 115 | 0.190 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2020 | 1254 | 0.190 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2020 | 175 | 0.190 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2022 | 112 | 0.190 |
Why?
|
| Odontogenic Tumors | 1 | 2020 | 12 | 0.180 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2021 | 43 | 0.180 |
Why?
|
| Databases, Factual | 3 | 2022 | 860 | 0.180 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 79 | 0.180 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2021 | 80 | 0.180 |
Why?
|
| Organs at Risk | 1 | 2020 | 40 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2666 | 0.170 |
Why?
|
| Immunotherapy | 2 | 2022 | 688 | 0.160 |
Why?
|
| Cystectomy | 2 | 2017 | 106 | 0.160 |
Why?
|
| Cytokines | 1 | 2023 | 806 | 0.160 |
Why?
|
| Aged | 5 | 2024 | 19144 | 0.160 |
Why?
|
| Radiotherapy | 2 | 2020 | 332 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 849 | 0.160 |
Why?
|
| Radiotherapy Dosage | 1 | 2020 | 469 | 0.160 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 6766 | 0.160 |
Why?
|
| Male | 7 | 2024 | 42464 | 0.160 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 1172 | 0.150 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 322 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 753 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2024 | 4309 | 0.140 |
Why?
|
| Carcinoma | 1 | 2020 | 438 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2021 | 9112 | 0.140 |
Why?
|
| Oncologists | 1 | 2017 | 36 | 0.140 |
Why?
|
| Radiation Oncologists | 1 | 2016 | 14 | 0.140 |
Why?
|
| Propensity Score | 1 | 2017 | 148 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2020 | 581 | 0.130 |
Why?
|
| Confidence Intervals | 1 | 2016 | 221 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2020 | 8209 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 294 | 0.130 |
Why?
|
| Geriatric Assessment | 1 | 2017 | 181 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2017 | 151 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 571 | 0.120 |
Why?
|
| Analysis of Variance | 1 | 2017 | 899 | 0.120 |
Why?
|
| Urinary Bladder | 1 | 2017 | 248 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 846 | 0.120 |
Why?
|
| Observer Variation | 1 | 2016 | 613 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 984 | 0.120 |
Why?
|
| Middle Aged | 5 | 2024 | 25996 | 0.120 |
Why?
|
| Female | 6 | 2024 | 46371 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2017 | 1496 | 0.110 |
Why?
|
| Prognosis | 2 | 2021 | 3783 | 0.110 |
Why?
|
| Radiographic Image Enhancement | 1 | 2015 | 463 | 0.110 |
Why?
|
| Adult | 4 | 2024 | 26684 | 0.100 |
Why?
|
| Time Factors | 1 | 2020 | 5333 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2017 | 2878 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2017 | 2304 | 0.080 |
Why?
|
| United States | 4 | 2020 | 7041 | 0.070 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 152 | 0.050 |
Why?
|
| Physics | 1 | 2020 | 21 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 305 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 219 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 195 | 0.040 |
Why?
|
| Research | 1 | 2020 | 251 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 497 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 280 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 279 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 953 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1247 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 358 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 834 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1877 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 3658 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1050 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1540 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 5523 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2641 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 2502 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 6362 | 0.010 |
Why?
|